Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesCardiologyblue cross blue shield - louisiana CVD Coverage Up…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Modifiedblue cross blue shield - louisianaPolicy AHS - G2050

    Cardiovascular Disease Risk Assessment

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy AHS - G2050 alerts

    Get alerted when Policy AHS - G2050 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage criteria for tests and panels used to assess cardiovascular disease risk (lipid panels, biomarkers, and related assays) and specifies which tests meet or do not meet Blue Cross and Blue Shield of Louisiana coverage for providers requesting CVD risk assessment testing.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyCardiovascular Disease Risk Assessment
    Policy CodePolicy AHS - G2050
    Change TypeMaterial coverage criteria revisions and frequency updates
    Effective DateSep 15, 2026
    Last ReviewSep 1, 2023
    Next Review DateN/A
    Key ActionOrder lipid panels per updated intervals: routine screening every 5 years and annually for individuals at increased CVD risk; document indication and risk-enhancing factors to support testing.
    SourceLink
    POLICY UPDATE CHANGES

    As risk factors (not general screening) are age dependent, 'For individuals 18 years of age or older' removed from CC1.

    CC1.a.i. changed 'Every 4 years' to 'Every 5 years' based on NLA updates.

    Added CC1.b.xiii.–xv.: family history of elevated lipids; premature heart disease; history of stroke.

    CC1.c.iii annual recommendation changed to 'Every three to twelve months as clinically indicated.'

    Removed CC4 allowing hs-CRP (high-sensitivity C-reactive protein) testing for general use.

    Former CC5 renumbered to CC4 and now states: 'For cardiovascular disease risk assessment, CRP testing (conventional measurement or high-sensitivity measurement) DOES NOT MEET COVERAGE CRITERIA.'

    Former CC8 renumbered to CC7 and added 'myeloperoxidase'.

    CC10: Lp-PLA2 is never supported for approval; removed 'For CVD risk assessment'.

    CC3 clarified that Lp(a) screening is once per lifetime and should occur after age 18.

    Added clarification that 10-year ASCVD risk cannot be calculated for individuals 39 years of age or younger.

    Moved a prior subcriterion into the annual testing group for patients on long-term drug therapy that elevates dyslipidemia risk.

    Added family history of elevated lipids, premature heart disease, and history of stroke as risk factors (CC1.b.xiii–xv).

    Removed the age qualifier 'For individuals 18 years of age or older' from CC1 and changed lipid screening interval from every 4 years to every 5 years in CC1.a.i.

    Every 5 yearsRoutine lipid screening interval
    AnnuallyLipid panel for increased risk
    Once (lifetime)Lp(a) measurement
    Not coveredCRP testing stance
    Not coveredhs-cTnT for outpatient risk
    2025Guideline updates cited

    Coverage Criteria for Cardiovascular Risk Assessment Tests

    Lipid panel testing (simple lipid panel)

    Covered when ANY of the following conditions are met:

    To screen for CVD risk: Every 5 years for individuals ages 18 to 79 years; annually for individuals at increased 10-year ASCVD risk per 2013 ACC/AHA Pooled Cohort Equations (10-year ASCVD risk cannot be calculated for individuals 39 years of age or younger).age 18-79; annual for increased risk

    See Note 2 for PCE risk factors (gender, age, race, smoking, hypertension, diabetes, total cholesterol, HDL-C, LDL-C).

    Annual testing for increased dyslipidemia risk: Annually for individuals at increased risk of dyslipidemia due to any of: obesity/metabolic syndrome; nephrotic syndrome; hypothyroidism; hyperthyroidism; pancreatitis; diabetes; chronic kidney disease; Cushing syndrome; pregnancy; cholestatic liver disease; lipid metabolism disorders (e.g., Gaucher disease in adults); being on long-term drug therapy requiring lipid monitoring (e.g., isotretinoin, antipsychotics); family history of elevated lipids; premature heart disease; or history of stroke.annual
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyCardiovascular Disease Risk Assessment
    Policy CodePolicy AHS - G2050
    Change TypeMaterial coverage criteria revisions and frequency updates
    Effective DateSep 15, 2026
    Last ReviewSep 1, 2023
    Next Review DateN/A
    Key ActionOrder lipid panels per updated intervals: routine screening every 5 years and annually for individuals at increased CVD risk; document indication and risk-enhancing factors to support testing.
    SourceLink
    On This Page
    Coverage Criteria for Cardiovascular Risk Assessment TestsProcedure Codes, Thresholds, and Key Numeric ValuesProvider Actions, Documentation, and Prior Authorization NotesBackground and ScopeDefinitions and Test DescriptionsPolicy Changes and Revision History

    (list drawn from policy CC1.b).

    Monitoring around statin therapy: To establish baseline before initiating statin therapy; repeat every 4–12 weeks after initiation or change; then every 3–12 months as clinically indicated while on therapy (applies to individuals with hyperlipidemia, transplant patients).4–12 weeks; 3–12 months

    From CC1.c in policy; used to assess adherence and response.

    Monitoring for persons on ART (HIV): For HIV-positive individuals starting or receiving antiretroviral therapy: baseline before ART; every 1–3 months after initiation or change; every 6–12 months when no medication changes have occurred.1–3 months; 6–12 months

    From CC1.d in policy and HIV guidance incorporated into policy text.

    Apolipoprotein B (apoB)

    Covered when ANY of the following are met (measurement no more than once every 4 weeks):

    ApoB indications: Measurement (no more than once every 4 weeks) for individuals with hypertriglyceridemia; individuals with diabetes mellitus; individuals with obesity or metabolic syndrome; other dyslipidemias (e.g., very low LDL-C); individuals on lipid-lowering therapy; and individuals suspected of familial dysbetalipoproteinemia or familial combined hyperlipidemia.<=1 per 4 weeks

    Consistent with NLA/ESC guidance to consider apoB when TG are high or LDL-C is discordant.

    Lipoprotein(a) (Lp(a))

    Covered when ALL of the following are met:

    Lp(a) coverage: Measurement once per lifetime when the individual is 18 years of age or older.once per lifetime; age ≥18

    Aligned with policy CC3 and NLA recommendation to measure Lp(a) at least once in adults to identify very high inherited levels.

    Tests and panels NOT meeting coverage criteria

    The following tests do not meet coverage criteria due to lack of sufficient evidence:

    Not covered biomarkers/panels: C-reactive protein testing (conventional or high-sensitivity), high-sensitivity cardiac troponin T (hs-cTnT) for outpatient CVD risk assessment, homocysteine testing for CVD risk, novel lipid and non-lipid biomarkers (e.g., apolipoprotein AI, apolipoprotein E, BNP/NT-proBNP for risk assessment, cystatin C, fibrinogen, leptin, LDL/HDL subclasses, myeloperoxidase), multi-biomarker cardiovascular risk panels (other than a simple lipid panel), intermediate density lipoproteins (remnant cholesterol), lipoprotein-associated phospholipase A2 (Lp-PLA2), long-chain omega-3 fatty acid measurement in red blood cell membranes, and all other tests not specified as covered.

    These tests are stated in the policy as not meeting coverage criteria (CC4–CC12).

    Markers supported for selective clinical use

    Markers with reported clinical utility or stronger supporting evidence in this excerpt

    GlycA: Glycoprotein acetyls (GlycA) demonstrated better within-subject correlation over 9–10 years than CRP and predicted future hypertension and metabolic syndrome in adolescent and young adult cohorts (study n≈3306), suggesting potential utility in early risk detection.

    Selected from biomarker evidence summaries in policy.

    ApoB concentration reflects LDL particle number and is associated with atherosclerosis; societies (ESC/EAS, NLA) recommend ApoB assessment particularly when TG are elevated, in diabetes, obesity/metabolic syndrome, or very low LDL-C, and as an adjunct to refine risk beyond LDL-C/non-HDL-C.

    Evidence and guideline recommendations cited in policy text.

    Lp(a): Lipoprotein(a) is an independent, primarily genetically determined atherogenic factor with a continuous log-linear relationship to ASCVD risk; baseline levels ≥30 mg/dL and on-statin levels ≥50 mg/dL have been associated with increased hazard ratios in large studies.baseline ≥30 mg/dL; on-statin ≥50 mg/dL

    Policy cites epidemiology and NLA guidance supporting selective clinical use.

    BNP/NT-proBNP are established diagnostic and prognostic markers in heart failure; in HFrEF, NT-proBNP reduction to ≤1,000 pg/ml during guideline-directed therapy is associated with better outcomes.≤1,000 pg/ml

    Supported as prognostic markers rather than routine primary prevention risk screens.

    hs-CRP (selective use): High-sensitivity CRP assays detect low-range CRP and elevated levels predict future MI, stroke and other outcomes; selective use to refine risk (e.g., when 10-year risk is borderline/intermediate) may be informative though routine population screening is not recommended.hs-CRP >3.0 mg/L often considered high

    Selective integration into practice noted; broader coverage was removed in recent revisions.

    Markers not routinely recommended

    Markers with uncertain or insufficient evidence

    Cystatin C: No published literature proves effectiveness of cystatin C as a cardiovascular biomarker for routine use; confounding by inflammation limits interpretation.

    Policy states cystatin C is not routinely used for CVD risk assessment.

    Leptin: Evidence is inconsistent: a meta-analysis found no independent association between leptin and CVD after adjustment for other risk factors; further research is required.

    Policy cites meta-analysis and cohort data with conflicting findings.

    Homocysteine: Although elevated homocysteine is associated with CVD risk, trials lowering homocysteine have not consistently reduced CVD events; routine testing for CVD risk assessment is not consistently recommended.

    Policy classifies homocysteine testing as not meeting coverage for CVD risk assessment.

    ACC/AHA risk estimation and selective use of adjunct tests

    Use of risk estimation and adjunct testing per ACC/AHA guidance

    Primary ASCVD risk assessment: Adults aged 40–75 being evaluated for primary prevention should undergo 10-year ASCVD risk estimation (Pooled Cohort Equations) and have a clinician–patient risk discussion before initiating pharmacologic therapy.age 40–75

    ACC/AHA 2019 guidance cited in policy.

    When additional testing may be considered: If treatment decision remains uncertain after quantitative risk assessment, one or more adjuncts (family history, hs-CRP, ABI, or coronary artery calcium) may be considered to inform shared decision-making; CIMT is not recommended for routine use.uncertain decision

    ACC/AHA recommendations for selective adjunct testing.

    NLA lipid and Lp(a) guidance

    NLA recommendations on lipid and Lp(a) testing

    Lipid measurement timing and indications: Follow up abnormal screening lipids with fasting measurement; repeat lipid measurements 4–12 weeks after a change in lipid-lowering therapy and every 3–12 months for those on stable medication as indicated.4–12 weeks; 3–12 months

    NLA recommendations summarized in policy (strengths/evidence in source).

    Lp(a) measurement indications: Measure Lp(a) to refine risk in adults with family history of premature ASCVD, individuals with premature ASCVD, primary severe hypercholesterolemia (LDL ≥190 mg/dL), very high ASCVD risk, intermediate/borderline 10-year risk when statin decision is uncertain, or unexplained high residual risk; NLA 2024 update recommends at least one Lp(a) measurement in all adults.Lp(a) ≥50 mg/dL or ≥125 nmol/L as risk-enhancing

    Policy aligns coverage with NLA statements.

    Covered with clinical criteria

    Society-endorsed testing and monitoring scenarios extracted from referenced guidelines

    Lp(a) testing recommended indications: Measure Lp(a) at least once in all adults (NLA); selective youth screening for FH, family history of premature ASCVD, ischemic stroke of unknown cause, or first-degree relatives with elevated Lp(a). Consider Lp(a) in primary prevention when 10-year ASCVD risk is borderline or intermediate or when statin decision is uncertain; consider in recurrent/refractory ASCVD or calcific aortic stenosis.

    Derived from NLA and guideline excerpts.

    Lipid monitoring after therapy changes: Obtain lipid measurements 4–12 weeks after initiating or changing lipid-lowering therapy and periodically thereafter (every 3–12 months as appropriate) to assess response and adherence.4–12 weeks; 3–12 months

    NLA guidance reiterated in policy.

    hs-CRP selective protocol: When used selectively to refine primary prevention decisions, hs-CRP may be measured twice (optimally 2 weeks apart) in metabolically stable patients; routine population screening is discouraged.two measurements ~2 weeks apart

    CDC/AHA workshop referenced in policy for selective hs-CRP use.

    Routine lipid screening frequency: All adults should have lipids evaluated at least every 5 years; adults at increased risk (e.g., diabetes, family history, premature disease) should be checked annually.every 5 years (routine); annually for increased risk

    Policy CC1 aligns with NLA and other guideline recommendations.

    Guideline-based clinical recommendations

    Recommendations from multiple guidelines for when to use risk tools, biomarkers, or imaging in primary prevention:

    Age-based risk tool selection: Use SCORE for apparently healthy people <70 years; use SCORE2-OP for people >70 years; select appropriate risk model based on guideline and patient age/context.age-based

    ESC/EAS guidance cited in policy.

    Use of imaging as risk modifier: Consider subclinical coronary atherosclerosis by imaging or increased CAC score by CT as risk modifiers in individuals at moderate risk or near treatment decision thresholds to improve classification and guide therapy decisions.moderate risk or near threshold

    ESC/EAS, ASCP, CCS support selective CAC use.

    Biomarker measurement guidance: Measure LDL-C as primary lipid test; consider ApoB when TG are elevated, in diabetes, obesity, or very low LDL-C; measure Lp(a) at least once in adulthood to identify very high inherited levels.clinical context

    Consensus across multiple societies in policy excerpts.

    LDL-C initiation thresholds: Consider pharmacologic LDL-C–lowering therapy in primary prevention for persons at very high risk with LDL-C >70 mg/dL (1.8 mmol/L) or at high risk with LDL-C >100 mg/dL (2.6 mmol/L); consider lower thresholds for certain risk groups per guideline updates.LDL-C values by risk category

    ESC/EAS 2025 recommendations summarized in policy.

    Guideline-based coverage criteria

    Recommendations extracted from cited guidelines — covered when clinically indicated per guideline statements

    HIV-infected patients on ART: Obtain fasting lipid profile prior to and within 1–3 months after starting ART and every 6–12 months if abnormal or other cardiovascular risk factors present; consider HbA1c monitoring and alternate screening thresholds in patients on ART.time-based

    HIV Medicine Association/IDSA guidance incorporated into policy CC1.d.

    VA/DoD primary prevention guidance: Suggest against offering CVD risk assessment more frequently than every 5 years in patients >40 without new risk factors; suggest against routine lipid panel more frequently than every 10 years for persons not on statin therapy; generally advise against routine CAC and additional risk markers except when they affect decisions in intermediate-high risk patients.guideline-based

    VA/DoD guidance referenced in policy revision history.

    ESC 2021 guidance: Routine assessment of circulating or urinary biomarkers is not recommended for CVD risk stratification; repeat risk assessments every 5 years and more often for higher risk patients; selective age-based systematic assessment noted.time/age-based

    ESC task force statements summarized in policy.

    Renal transplant lipid management (NHS): Measure baseline transaminases before starting statin; measure TC, HDL, LDL after 3 months aiming for >40% LDL reduction; measure transaminases at 3 and 12 months.3 and 12 months

    NHS 2025 recommendations included in policy for transplant patients.

    Revised coverage criteria highlights

    Summary of coverage criteria changes and stances noted in revision history

    CC1 revisions: Operational edits: removed the phrase 'For individuals 18 years of age or older' from CC1; updated routine lipid screening interval from every 4 years to every 5 years; added clarification that 10-year ASCVD risk cannot be calculated for individuals 39 years of age or younger; added family history of elevated lipids, premature heart disease, and history of stroke to annual testing indications.

    From policy revision history dated 09/15/2026.

    Lp(a) frequency and age: Clarified that Lp(a) screening is once per lifetime and should occur after age 18.once per lifetime; after age 18

    Reflects edits in revision history (CC3).

    CRP stance updated: Removed allowance for routine hs-CRP screening; CRP testing (conventional or high-sensitivity) DOES NOT MEET COVERAGE CRITERIA for general CVD risk assessment per guideline alignment (VA/DoD, USPSTF).N/A

    Policy revision resulted in removal of prior CC4 and renumbering.

    Lp-PLA2 and other removals: Lp-PLA2 is not supported for approval and was removed from supportive coverage statements; other novel biomarkers/panels remain not supported for routine coverage.N/A

    Explicit in revision history entries.

    Key Coverage Criteria (excerpt)

    Selected coverage rules and frequency updates extracted from revision history:

    Lp(a) Screening: Measurement of lipoprotein(a) once per lifetime, with testing performed after the individual is 18 years of age.age ≥18; once per lifetime

    Policy CC3 and revision entries clarify timing and frequency.

    Routine lipid screening interval update: Routine lipid panel screening interval updated from every 4 years to every 5 years for adults (CC1.a.i).every 5 years

    Reflects NLA-aligned policy change documented in revision history.

    Increased-risk annual lipid screening: Lipid panel may be performed annually for individuals at increased risk of dyslipidemia or those on long-term therapies that elevate dyslipidemia risk.annual

    CC1.b and moved CC1.d justify annual testing in specified conditions.

    CRP/hs-CRP coverage removal: CRP testing (conventional or high-sensitivity) does not meet coverage criteria for general cardiovascular disease risk assessment; prior allowances for hs-CRP were removed based on guideline updates.N/A

    Documented policy revision and guideline alignment (VA/DoD, USPSTF).

    The policy explicitly excludes a set of inflammatory, cardiac injury, metabolic, and multi-marker assays from meeting coverage criteria for cardiovascular disease (CVD) risk assessment. Specifically, CRP testing (conventional or high-sensitivity), high-sensitivity cardiac troponin T (hs-cTnT), homocysteine testing, novel lipid and non-lipid biomarkers (e.g., apolipoprotein AI/E, BNP, cystatin C, fibrinogen, leptin, LDL/HDL subclasses, myeloperoxidase), and multi-biomarker CVD risk panels (other than simple lipid panels) are listed as not meeting coverage criteria. The policy also names intermediate-density lipoproteins, Lp-PLA2, long-chain omega-3 fatty acid measurement in RBC membranes, and other unspecified tests for assessing CVD risk as excluded from coverage for routine CVD risk assessment.

    The document states that cystatin C is not routinely used as a cardiovascular disease biomarker. Although cystatin C has been proposed in the context of kidney function and inflammation, the policy notes there is no published evidence proving its effectiveness for predicting cardiovascular risk and that potential confounding (e.g., inflammation) limits its routine use in CVD risk assessment.

    Proprietary multi-marker cardiovascular risk panels (commercially marketed profiles that combine lipids, inflammatory, genetic, and metabolic markers and report algorithm-derived scores) are not supported by demonstrated clinical utility per the policy. The policy explains that the clinical utility of these panels is lacking and the impact of their results on patient management is unknown, and therefore such multi-biomarker panels (other than a simple lipid panel) do not meet coverage criteria.

    CDC/AHA guidance is cited regarding high-sensitivity C-reactive protein (hs-CRP): hs-CRP measurement was recommended by the CDC/AHA workshop to be limited to two measurements (optimally two weeks apart) in metabolically stable patients when used as an adjunct to major risk factors, but the Writing Group advised against screening the entire adult population with hs-CRP as a public health measure. The policy reflects this caution by removing prior allowance for general hs-CRP screening.

    Multiple guideline sources are summarized to indicate that routine use of certain advanced or novel biomarkers and routine coronary artery calcium (CAC) testing is not recommended for broad population screening. The ASCP, ESC task force, and VA/DoD guidance each caution against routine ordering of expanded lipid or additional biomarker testing for general risk stratification, and the policy was revised to remove general allowance for hs-CRP and to limit routine use of imaging or additional markers except when results would meaningfully affect clinical decision-making.

    Guideline excerpts note that routine use of CAC, hs-CRP, ankle-brachial index (ABI), and other additional risk markers is generally not recommended for routine CVD risk assessment. These tools may be considered selectively—typically for individuals at intermediate or near-threshold risk where results would alter management—but are not supported for routine screening in low-risk or asymptomatic populations.

    The policy makes clear that CRP testing (conventional or high-sensitivity) is excluded from meeting coverage criteria for cardiovascular disease risk assessment. Following revision history and guideline updates, the document states that CRP testing does not meet coverage criteria for CVD risk assessment except where explicitly described in prior, now-removed allowances.

    Although Lp-PLA2 has been evaluated in multiple studies and is biologically plausible as a vascular inflammatory marker, the policy states that measurement of Lp-PLA2 DOES NOT MEET COVERAGE CRITERIA and that Lp-PLA2 testing is not supported for approval for cardiovascular disease risk assessment. Clinical trials of Lp-PLA2 inhibitors did not demonstrate improved patient outcomes, contributing to the noncoverage stance.

    The policy reiterates that CRP testing (both conventional and high-sensitivity) does not meet coverage criteria for CVD risk assessment, reflecting the removal of prior permissive language for general hs-CRP screening. This change aligns with recent guideline recommendations advising against routine population screening with hs-CRP and with USPSTF/VA/DoD positions that limit adjunct marker use.

    The policy states that all tests listed under the 'does not meet coverage criteria' section are considered not medically necessary for cardiovascular disease risk assessment. This includes CRP/hs-CRP, hs-cTnT, homocysteine, novel lipid and non-lipid biomarkers, proprietary multi-marker panels, intermediate-density lipoproteins, Lp-PLA2, and long-chain omega-3 fatty acid measurements in RBC membranes.

    The policy notes that while elevated homocysteine levels are associated with increased CVD risk, routine homocysteine testing for CVD risk assessment is not consistently recommended because interventions that lower homocysteine have not been shown to reduce cardiovascular events. Therefore, its clinical utility for routine risk screening is unproven.

    Consistent with evidence summaries and guideline guidance, the policy does not support routine testing of homocysteine, Lp-PLA2, or proprietary multi-marker cardiovascular risk panels for CVD risk assessment. The document emphasizes that available data do not demonstrate consistent clinical utility or outcome benefit to justify routine coverage for these tests.

    The CDC/AHA workshop concluded that hs-CRP measurement should be limited to targeted clinical use (two measurements, optimally two weeks apart, in metabolically stable patients) and explicitly advised against screening the entire adult population with hs-CRP as a public health measure. The policy reflects this by not supporting hs-CRP as a broad public health screening tool.

    The USPSTF concluded that current evidence is insufficient to recommend adding ABI, hs-CRP, or CAC to traditional risk assessment in asymptomatic adults, and other guideline groups (VA/DoD) similarly advise against routine use of these adjunct markers. The policy incorporates these positions in limiting routine use of these tests for primary prevention screening.

    Guideline-based 'Not Medically Necessary' positions are summarized: routine assessment of circulating or urinary biomarkers (including hs-CRP and various apolipoproteins) and routine advanced testing (expanded lipid panels, CAC) are generally not recommended for routine risk stratification. The policy follows these guideline-based recommendations by restricting routine coverage to tests and indications explicitly described in coverage criteria.

    Following recent review and guideline updates, the policy states that high-sensitivity CRP testing for general cardiovascular risk assessment is not supported and does not meet coverage criteria. Historical language that allowed hs-CRP for broader screening was removed in favor of guideline-aligned, more restrictive use.

    The policy explicitly states that homocysteine testing for cardiovascular disease risk assessment, screening, evaluation, and management DOES NOT MEET COVERAGE CRITERIA. This stance is reinforced by the lack of evidence that lowering homocysteine reduces CVD outcomes and by cross-references to other policies addressing homocysteine-related metabolic conditions.

    Procedure Codes, Thresholds, and Key Numeric Values

    Applicable CPT/HCPCS procedure codesmixed
    No codes listed
    No explicit codes listed in this excerptmixed
    No codes listed
    Covered CPT/HCPCS Codes (selected list)mixed
    80061Lipid panel.
    82172Apolipoprotein, each.
    82465Cholesterol, serum or whole blood, total.
    82610Cystatin C.
    83090Homocysteine.
    83695Lipoprotein (a).
    83698Lipoprotein-associated phospholipase A2 (Lp-PLA2).
    83700Lipoprotein, blood; electrophoretic separation and quantitation.
    83701Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed.
    83704Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by NMR).
    1–10 of 24
    1/3
    Proprietary/Specific-Method CodesHCPCS
    0052ULipoprotein, blood, high resolution fractionation and quantitation (VAP Cholesterol Test).
    0308UCardiology (CAD), analysis of 3 proteins with algorithmic risk score (HART CADhs®).
    0309UCardiology (CVD), analysis of 4 proteins with algorithmic risk score (HART CVE®).
    0377UCardiovascular disease, quantification of advanced lipoprotein profile by NMR (Liposcale®).
    0415UCardiovascular disease (ACS), multi-marker immunoassay with algorithmic risk score (SmartHealth Vascular Dx™).
    0541UHDL reverse cholesterol transport panel with pCAD Score (Quest Diagnostics®).
    References to coding or external coverage (no explicit codes in excerpt)mixed
    No codes listed
    Updated/Added CPT CodesCPT
    0308ULaboratory code (revised name noted in document)
    0309ULaboratory code (revised name noted in document)
    0541UCPT code added (04/01/2025 off-cycle coding modification)
    0415UCPT code added (10/01/2023)
    0019MCPT code added (10/01/2023)
    84512Mapped to policy; updated in 2025
    Removed CPT CodesCPT
    81402Removed CPT code
    81403Removed CPT code
    81404Removed CPT code
    81405Removed CPT code
    81406Removed CPT code
    81407Removed CPT code
    81408Removed CPT code
    inv-38: Persistently elevated primary hypertriglyceridemia numeric threshold
    Persistently elevated primary hypertriglyceridemia≥175 mg/dL
    ContextListed by ACC/AHA as a risk-enhancing factor in Note 2
    Relation to monitoringConsider more frequent lipid testing when TG are elevated per NLA guidance
    inv-39: Elevated high-sensitivity C-reactive protein threshold
    Elevated high-sensitivity C-reactive protein (hs-CRP)≥2.0 mg/L
    CDC/AHA measurement protocolMeasure hs-CRP twice (optimally 2 weeks apart) and average in mg/L in metabolically stable patients
    Policy coverage notehs-CRP removed from general screening coverage; may be considered selectively per guidelines
    inv-40: Elevated apoB risk threshold
    Elevated apolipoprotein B (ApoB) risk threshold≥130 mg/dL
    LDL equivalenceApoB ≥130 mg/dL corresponds to LDL-C ≥160 mg/dL (risk-enhancing)
    IndicationsConsider measurement with triglyceride ≥200 mg/dL or other discordance per guideline
    inv-41: Elevated Lp(a) risk threshold
    Elevated Lipoprotein(a) (Lp[a]) risk threshold≥50 mg/dL or ≥125 nmol/L
    Relative indicationFamily history of premature ASCVD is a relative indication for measurement
    Risk-enhancing roleConsidered a risk-enhancing factor by ACC/AHA and other societies
    inv-42: Lp(a) risk thresholds — baseline and on-statin thresholds
    Baseline Lp(a) level associated with increased riskbaseline ≥30 mg/dL
    On-statin Lp(a) level associated with increased riskon-statin ≥50 mg/dL
    Very high inherited level to identify lifetime risk>180 mg/dL (>430 nmol/L)
    inv-43: NT-proBNP prognostic threshold
    NT-proBNP prognostic threshold (HFrEF)≤1,000 pg/ml associated with better outcomes
    Biologic roleNT-proBNP is released with ventricular stress and used diagnostically and prognostically in heart failure
    Source trialGUIDE-IT trial findings cited for prognostic use
    inv-44: Biomarker thresholds cited — examples like troponin I quartiles, hs-CRP, TG, Lp(a)
    Troponin I exampleHighest quartile ≥5.2 ng/L (vs ≤3.1 ng/L) associated with higher CVD risk
    hs-CRP examplehs-CRP ≥2.0 mg/L noted as a risk-enhancing cutoff
    Primary hypertriglyceridemia≥175 mg/dL cited as risk-enhancing
    Lp(a) exampleLp(a) ≥50 mg/dL or ≥125 nmol/L cited as risk-enhancing
    inv-45: Severe hypercholesterolemia numeric threshold
    Severe hypercholesterolemia thresholdLDL-C ≥190 mg/dL
    Reporting guidanceDesignate LDL-C ≥190 mg/dL as severe hypercholesterolemia on reports
    Pediatric noteLDL-C ≥160 mg/dL considered severe in children (NLA guidance)
    inv-46: Potentially actionable hypertriglyceridemia threshold
    Potentially actionable hypertriglyceridemiaFasting triglycerides (TG) ≥500 mg/dL
    Reporting recommendationReport fasting TG ≥500 mg/dL as hypertriglyceridemia for clinical action
    Related risk noteTG >150 mg/dL contributes to metabolic syndrome definition; consider non-HDL/apoB when TG elevated
    inv-47: LDL-C thresholds for initiating pharmacological therapy (primary prevention)
    LDL-C threshold — very high risk (initiate pharmacologic therapy)>1.8 mmol/L (70 mg/dL)
    LDL-C threshold — high risk (initiate pharmacologic therapy)>2.6 mmol/L (100 mg/dL)
    Clinical considerationConsider therapy at lower LDL-C thresholds in certain categories (e.g., very high risk >1.4 mmol/L [55 mg/dL])
    inv-48: Lp(a) lifetime measurement threshold for very high inherited levels
    Lp(a) lifetime measurement to identify very high inherited levels>180 mg/dL (>430 nmol/L)
    RationaleIdentifies lifetime ASCVD risk comparable to heterozygous familial hypercholesterolemia per ESC/EAS guidance
    Screening frequencyOne-time measurement in adulthood to detect very high inherited levels
    inv-49: Non-HDL-C / apoB preference when TG >1.5 mmol/L
    When TG >1.5 mmol/L (≈133 mg/dL)Prefer non-HDL-C or apoB over LDL-C for assessment
    Targets citedNon-HDL-C target <2.6 mmol/L or apoB <0.8 g/L in intermediate or high risk individuals
    RationaleRemnant cholesterol and TG elevation reduce LDL-C accuracy; apoB/non-HDL-C better reflect risk
    inv-50: HIV ART HbA1c cutoff for diabetes screening in patients on ART
    HIV ART HbA1c cutoff for diabetes screeningHbA1c cutoff of 5.8% may be used for diabetes screening in patients on ART (alternative to 6.5%)
    Monitoring intervalMeasure fasting lipid profile prior to and within 1–3 months after starting ART and every 6–12 months if abnormal or other risk factors present
    Guideline sourceHIV Medicine Association/IDSA guidance
    inv-51: Renal transplant LDL reduction target monitoring guidance
    Renal transplant LDL reduction monitoring targetAim for >40% reduction in LDL levels after therapy
    Monitoring scheduleMeasure TC, HDL and LDL after 3 months of therapy; measure transaminases at 3 and 12 months
    Further monitoringNo further routine monitoring unless indicated
    inv-52: Lp(a) screening frequency — once per lifetime (after age 18)
    Lp(a) screening frequencyOnce per lifetime
    Policy age constraintScreening to occur after age 18 (adult measurement)
    RationaleClarified in revision history to limit repeat measures and avoid routine serial testing
    inv-53: Age for Lp(a) screening — after 18 years of age
    Age for Lp(a) screeningAfter 18 years of age
    Coverage statementMeasurement once per lifetime meets coverage criteria when performed after age 18
    Related guidanceNLA and ESC recommend one-time adult measurement to identify inherited elevated Lp(a)
    inv-54: 10-year ASCVD risk calculation applicability — cannot be calculated for individuals 39 years of age or younger
    10-year ASCVD risk calculation applicabilityCannot be calculated for individuals 39 years of age or younger
    Policy noteAdded clarification in CC1 wording; use Pooled Cohort Equations (PCEs) for eligible ages
    Clinical implicationRisk-enhancing factors may be used for younger individuals where PCE not applicable

    Provider Actions, Documentation, and Prior Authorization Notes

    Prior Authorization

    Prior authorization: coverage based on meeting clinical criteria

    No explicit prior authorization requirements are stated in this policy excerpt; coverage is determined by whether the requested test meets the clinical coverage criteria and specified intervals.

    Prior Authorization

    Prior authorization: none specified in excerpt

    There are no separate prior authorization statements in the guideline excerpts provided; follow the policy's clinical coverage criteria for test ordering.

    Note

    Proprietary panel coverage: panels lack demonstrated clinical utility

    Proprietary multi-marker cardiovascular risk panels are listed as commercially available examples but the policy states their clinical utility is lacking and they do not meet coverage criteria for CVD risk assessment.

    • Examples include Genova Cardio Check™, Cleveland HeartLab CVD profiles, and other named panels listed in the policy.
    • Impact on patient management is unknown and such panels do not meet coverage criteria.
    Documentation Required

    Lipid monitoring frequency for long-term therapy

    When monitoring long-term anti-lipid therapy, an annual lipid panel is considered reasonable; CMS guidance also allows up to six measurements in the first year for monitoring dietary or pharmacologic therapy.

    • Annual lipid panel usually adequate while on long-term therapy.
    • Any single component may be medically necessary up to six times in the first year for monitoring therapy.
    Prior Authorization

    Prior authorization: not specified in guideline excerpts

    No explicit prior authorization requirements are specified in the cited guideline excerpts; clinicians should follow guideline recommendations and the policy's coverage criteria.

    Billing Rule

    Coding: use listed CPT/HCPCS codes when ordering tests

    The policy lists applicable CPT/HCPCS procedure codes for covered tests; providers must use the listed CPT/HCPCS codes when ordering and billing these tests.

    • Examples include 80061 (lipid panel), 83695 (Lp[a]), 86141 (hsCRP), and proprietary codes such as 0308U/0309U.
    • Use the policy-listed codes on claims and follow any payer-specific prior-authorization rules for proprietary tests.
    Prior Authorization

    Prior authorization implications after policy updates

    Policy updates changed testing frequencies and supported indications; if an ordered test does not meet the coverage criteria in this policy (for example, tests removed from coverage), prior authorization or claim denial may occur.

    • Recent revisions removed allowance for hs-CRP for general screening and clarified Lp(a) frequency (once per lifetime).
    • Tests not meeting coverage criteria (e.g., Lp-PLA2, hs-CRP for general screening) may be subject to noncoverage.
    Billing Rule

    CPT code updates: new/revised laboratory codes

    Certain CPT/HCPCS laboratory codes were added or revised in recent updates (for example, CPT codes 0308U and 0309U); providers should be aware of these code updates when ordering proprietary or algorithm-based tests.

    • Noted updated/added codes include 0308U, 0309U, 0415U, 0541U, and others listed in the revision history and code tables.
    Note

    Provider action

    —

    Note

    Provider action

    —

    Step Therapy

    Discuss CVD risk and risk-enhancing factors before starting therapy

    Clinician-patient risk discussion is recommended prior to initiating pharmacologic preventive therapy; assess risk-enhancing factors to guide decisions about starting statins or other interventions.

    • Use 10-year ASCVD risk estimation (PCE) for adults 40–75 and individualize with risk-enhancing factors.
    • Discuss benefits and risks of pharmacologic therapy with the patient before initiating treatment.
    Note

    Provider action

    —

    Note

    Therapy thresholds: LDL‑C thresholds by risk category (clinical guidance)

    Guidelines describe LDL-C thresholds to guide initiation of pharmacologic LDL-C–lowering therapy by risk category (e.g., very high risk >70 mg/dL; high risk >100 mg/dL), which clinicians should use to inform treatment decisions.

    • ESC/EAS guidance: pharmacologic therapy recommended for very high risk with LDL-C >70 mg/dL and high risk with LDL-C >100 mg/dL.
    • Consider lower thresholds in selected high-risk categories per guideline statements.
    Documentation Required

    Statin monitoring in renal transplant patients: baseline and 3/12 month transaminases

    Measure baseline transaminases before starting statin therapy in renal transplant patients and monitor transaminases at 3 and 12 months after initiation as part of documented therapy monitoring.

    • Also measure TC, HDL, and LDL after 3 months aiming for >40% LDL reduction; further monitoring as indicated.
    Step Therapy

    Step therapy: none specified

    No step therapy rules are specified in this policy excerpt.

    Note

    Provider action

    —

    Documentation Required

    Documentation: record indication, age, and clinical context to support testing

    Document the clinical indication (screening vs increased-risk evaluation vs therapy monitoring), patient age, and relevant clinical context (e.g., diabetes, transplant status, HIV on ART) when ordering lipid, apoB, or Lp(a) testing to support medical necessity.

    • Include the specific purpose (e.g., baseline before statin, monitoring after therapy change) and applicable guideline-based interval.
    Documentation Required

    Documentation: justify specialized biomarker testing and rationale

    When ordering specialized biomarkers (e.g., GlycA, ApoB, Lp[a], hs‑CRP), document the specific indication and rationale for test selection because utility varies by marker and may affect coverage determination.

    • Provide rationale tied to clinical scenarios described in the policy (e.g., discordant LDL-C/apoB, family history, premature ASCVD).
    Documentation Required

    Lipid measurement timing: baseline and follow-up around therapy changes

    Document baseline fasting lipid panel prior to starting statin therapy and repeat lipid testing 4–12 weeks after initiation or dose change, then every 3–12 months as clinically indicated.

    • For persons on ART, obtain fasting lipid profile prior to and within 1–3 months after starting ART and every 6–12 months when stable.
    Documentation Required

    Laboratory reporting: identify extremely elevated LDL‑C and actionable values

    Lipid laboratory reports should flag desirable values and specifically identify extremely elevated LDL‑C (≥190 mg/dL) and potentially actionable triglycerides (e.g., TG ≥500 mg/dL).

    • Reports should clearly denote severe hypercholesterolemia and report actionable abnormal results.
    Documentation Required

    Recommended timing: measure LDL‑C 4–6 weeks after therapy changes

    Measure LDL‑C 4–6 weeks after initiation or intensification of lipid‑lowering therapy to assess response, and document timing and results in the medical record.

    • Follow-up lipid measurements thereafter per guideline intervals (e.g., every 3–12 months as clinically indicated).
    Documentation Required

    Required testing documentation: baseline and guideline-based follow-up lipid profiles

    Obtain and document baseline and follow-up lipid profiles per guideline-specified intervals (for example, fasting lipid profile prior to and within 1–3 months after starting ART and every 6–12 months if abnormal), and record these in the patient record to support coverage.

    • Document adherence, treatment changes, and interval results when used for monitoring therapy or risk reassessment.
    Documentation Required

    Documentation notes: indicate risk factors and frequency limits (e.g., Lp[a] once lifetime)

    Document the indication and relevant risk factors when ordering lipid and biomarker testing; note frequency limits such as Lp(a) screening once per lifetime and that Lp(a) measurement should occur after age 18.

    • Include supporting clinical details (family history, premature ASCVD, therapy monitoring) to demonstrate medical necessity.
    Documentation Required

    Documentation expectations: record risk‑enhancing factors and quantitative risk assessment

    When ordering risk-based tests, document risk‑enhancing factors and the use of a quantitative risk assessment tool (e.g., ACC/AHA Pooled Cohort Equations) to justify testing decisions; Lp(a) testing should be ordered once per lifetime after age 18 when indicated.

    • Record the PCE-calculated 10‑year ASCVD risk and any uncertainty prompting adjunct testing.
    Denial Risk

    Denial risk: tests that do not meet coverage criteria and may be denied

    Requests for CRP (conventional or high‑sensitivity), hs‑cTnT for outpatient risk stratification, homocysteine, Lp‑PLA2, intermediate density lipoproteins, proprietary multi‑marker panels, and other novel biomarkers for general CVD risk assessment will be denied because they do not meet coverage criteria.

    • Do not submit claims for these tests for general CVD risk assessment unless an allowed coverage criterion explicitly applies.
    Note

    Provider action

    —

    Prior Authorization

    Provider authorization: follow guideline recommendations (no explicit requirements)

    There are no explicit provider authorization steps stated in this section; follow the guideline and policy coverage criteria when ordering tests.

    Denial Risk

    Testing frequency implications: document indications for more frequent testing

    More frequent testing of total cholesterol, LDL‑C, and triglycerides may be indicated for marked elevations or after therapy changes; without a documented clinical indication, deviations from routine intervals risk noncoverage.

    • CMS allows more frequent measurement (up to six times the first year) for therapy monitoring and three times yearly after goals achieved in some situations.
    Denial Risk

    Denial triggers: not specified in this section

    Not applicable—the provided excerpts do not list specific payer denial triggers beyond the tests and uses identified as not meeting coverage criteria.

    Note

    Regulatory conflict resolution: government policy supersedes

    If this policy conflicts with applicable government policies (e.g., Medicare LCDs or NCDs), the government policy supersedes and will be used to make coverage determinations.

    Denial Risk

    Denied tests: hs‑CRP and Lp‑PLA2 not supported for general risk assessment

    Tests such as hs‑CRP and Lp‑PLA2 were removed or are not supported for cardiovascular disease risk assessment; submitting these for general CVD risk assessment may result in noncoverage or denial.

    • hs‑CRP allowance for general screening was removed in the revision history; Lp‑PLA2 is never supported for approval.
    Denial Risk

    CRP/hs‑CRP denials: claims not supported for general screening

    Claims for CRP testing (conventional or high‑sensitivity) for general CVD risk assessment are not supported when not described in coverage criteria; removal of prior allowances may lead to denial for broad screening use.

    • Policy explicitly states CRP testing DOES NOT MEET COVERAGE CRITERIA for CVD risk assessment.

    Background and Scope

    Cardiovascular disease is the leading cause of death and includes coronary heart disease, heart failure, hypertension, and stroke. Lipid profiles are the principal blood tests used for cardiovascular risk assessment, while a range of biomarkers have been proposed to add prognostic information but generally provide modest incremental value; certain patient groups (e.g., transplant recipients or those with metabolic or inflammatory conditions) may require more frequent monitoring.

    Definitions and Test Descriptions

    inv-88: Simple lipid panel definition — includes total cholesterol, HDL, LDL, triglycerides
    Simple lipid panel componentsTotal cholesterol; HDL cholesterol; LDL cholesterol; Triglycerides
    Optional reportsCalculated ratios such as total/HDL may also be reported
    ExclusionsApolipoproteins, particle number/size, and Lp(a) are not components of a simple lipid panel
    inv-89: Pooled Cohort Equations (PCEs) definition
    Pooled Cohort Equations (PCEs)Risk calculation tool (2013 ACC/AHA) to estimate 10-year ASCVD risk using age, sex, race, smoking, BP, diabetes, total cholesterol, HDL-C, and LDL-C
    LimitationPCE cannot calculate 10-year risk for individuals ≤39 years; clinician-patient risk discussion recommended
    RoleProvides population risk estimate; use risk-enhancing factors to individualize risk
    inv-90: Apolipoprotein B (Apo B) definition
    Apolipoprotein B (ApoB) definitionPrimary protein in LDL and VLDL; one ApoB-100 molecule per LDL particle representing particle number
    Clinical roleApoB concentration reflects LDL particle number and may add information beyond LDL-C; recommended for select patients
    Measurement considerationsUsed especially with high TG, diabetes, obesity, or very low LDL-C per ESC/NLA guidance
    inv-91: Lipoprotein(a) (Lp[a]) definition
    Lipoprotein(a) (Lp[a]) definitionAn LDL-like particle with atherogenic potential; serum levels largely genetically determined and associated with ASCVD risk
    Measurement methodsStandard method: density gradient ultracentrifugation; some ELISA methods may be affected by Apo(a) isoforms
    Clinical noteLp(a) has continuous log-linear relationship to ASCVD risk; one-time adult measurement recommended
    inv-92: BNP/NT-proBNP definition and prognostic use
    BNP/NT-proBNP definitionCardiac hormone released with ventricular stress; diagnostic and prognostic marker in heart failure
    Prognostic thresholdNT-proBNP ≤1,000 pg/ml associated with better outcomes in HFrEF
    Clinical useUsed to aid diagnosis and prognostication in heart failure; BNP-guided therapy remains controversial
    inv-93: High-sensitivity C-reactive protein (hs-CRP) definition
    High-sensitivity C-reactive protein (hs-CRP) definitionSensitive assay detecting low-range CRP concentrations used for cardiovascular risk assessment
    Measurement protocolCDC/AHA: measure hs-CRP twice (optimally 2 weeks apart) and average in mg/L in metabolically stable patients
    Policy stanceRemoved from general screening coverage; selective use may refine risk when decision uncertain
    inv-94: IDL / remnant cholesterol definition
    IDL / remnant cholesterol definitionCholesterol content of triglyceride-rich lipoproteins (VLDL and IDL fasting; VLDL, IDL, chylomicron remnants nonfasting), associated with inflammation and CVD risk
    EstimationCan be estimated from triglyceride levels when advanced testing not performed
    Clinical implicationElevated remnant cholesterol linked to low-grade inflammation and increased CVD risk
    inv-95: Lp-PLA2 definition
    Lp-PLA2 definitionAn inflammatory enzyme expressed in atherosclerotic plaques proposed as a vascular-specific biomarker
    EvidenceEpidemiologic studies show independent association with CVD but trials of inhibitors failed to improve outcomes
    Policy stanceLp-PLA2 is not supported for approval for CVD risk assessment
    inv-96: High-sensitivity cardiac troponin definition
    High-sensitivity cardiac troponin definitionSensitive biomarkers of cardiac injury (hs-cTnI, hs-cTnT) that can improve risk stratification beyond traditional factors
    Prognostic dataElevated hs-troponin associated with higher future CVD events and mortality in cohort studies
    Policy coveragehs-cTnT for outpatient CVD risk assessment does not meet coverage criteria in this policy excerpt
    inv-97: apolipoprotein B short definition
    ApoB (short) definitionApoB-100 is the major protein in LDL/VLDL; ApoB concentration represents LDL particle number
    Clinical useUseful when discordance between LDL-C and particle number exists; recommended in select patients
    Measurement frequencyCovered indications include measurement no more than once every 4 weeks when clinically indicated
    inv-98: hs-CRP measurement protocol (two measurements, optimal 2 weeks apart)
    hs-CRP measurement protocolTwo measurements, optimally 2 weeks apart, average expressed in mg/L in metabolically stable patients
    Repeat if abnormalIf abnormal, repeat testing and evaluate for infection/inflammation before interpreting for CVD risk
    Population screening stanceCDC/AHA recommends against screening entire adult population with hs-CRP
    inv-99: SCORE2 / SCORE2-OP definition
    SCORE2 / SCORE2-OP definitionSystematic Coronary Risk Evaluation tools to estimate 10-year fatal and non-fatal CVD risk in different age groups
    Age applicabilitySCORE recommended for <70 years; SCORE2-OP for older persons in some guidelines
    RoleUsed in European guidelines to guide risk estimation and treatment decisions
    inv-100: Coronary artery calcium (CAC) definition
    Coronary artery calcium (CAC) definitionCT-measured coronary artery calcium score used as imaging biomarker to refine risk classification
    Use caseConsidered for intermediate-risk patients or when treatment decisions are uncertain
    Guideline noteNot recommended for routine use in low-risk patients; recommended selectively by some societies
    inv-101: Proprietary cardiovascular risk tests — list of named proprietary assays
    Proprietary cardiovascular risk tests — examplesSOMAmer®, VAP (VAP Cholesterol Test), HART CADhs®, HART CVE®, Liposcale®, SmartHealth Vascular Dx™, HDL reverse cholesterol transport panel
    Policy stanceProprietary multi-marker panels lack demonstrated clinical utility; impact on management uncertain
    CodingSpecific HCPCS/CPT codes (e.g., 0019M, 0052U, 0308U, 0309U, 0377U, 0415U, 0541U) identify many proprietary tests
    inv-102: CAC usage note — imaging biomarker considered by some guidelines
    CAC usage noteImaging biomarker considered by some guidelines to refine risk in intermediate-high risk patients when results affect management
    Not routineRoutine CAC for low-risk patients generally not recommended
    Decision aidMay inform initiation or intensity of lipid-lowering therapy when PCE result is borderline or intermediate
    inv-103: Lp(a) screening — once per lifetime after age 18
    Lp(a) screening policy summaryMeasure Lp(a) once per lifetime after age 18
    RationaleClarified in revision history to avoid routine repeat testing and to identify inherited elevated levels
    Coverage noteOnce-per-lifetime measurement meets coverage criteria per policy update
    inv-104: hs-CRP — removed from coverage for general CVD risk assessment per recent guideline alignment
    hs-CRP policy changeRemoved from coverage for general cardiovascular disease risk assessment per recent guideline alignment (VA/DoD, USPSTF)
    Selective useMay be measured selectively to refine risk when treatment decision uncertain, but not for population screening
    Measurement protocol noteCDC/AHA recommend two measurements ~2 weeks apart in metabolically stable patients
    inv-105: Risk-Enhancing Factors — definition and role in modifying risk beyond PCE
    Risk-Enhancing Factors — definitionAdditional clinical or laboratory features that modify individualized cardiovascular risk beyond the PCE-calculated risk
    ExamplesFamily history of premature ASCVD, persistent hypertriglyceridemia, hs-CRP elevation, elevated ApoB, elevated Lp(a), ABI <0.9, chronic inflammatory conditions
    Role in careUsed to inform clinician-patient risk discussion and guide preventive therapy decisions when PCE alone is insufficient

    Policy Changes and Revision History

    2026-09-15policy_revisionLatest

    Clinical Advisory Board review updated coverage criteria: removed the age qualifier from CC1, changed routine lipid screening interval from every 4 years to every 5 years, clarified that 10-year ASCVD risk cannot be calculated for individuals 39 years or younger, moved elevated-risk/long-term therapy testing into annual testing group, added family history of elevated lipids/premature heart disease/history of stroke to risk factors, updated monitoring frequency for therapy to 'Every three to twelve months as clinically indicated', and removed allowance for general hs-CRP use (CRP testing now does not meet coverage criteria).

    2025-11-15policy_update

    Updated background, guidelines, and references; CC3 clarified that Lp(a) screening is once per lifetime and should occur after age 18.

    2025-04-01coding_and_criteria_update

    Off-cycle coding modification added CPT code 0541U and revised laboratory names for CPT codes 0308U and 0309U; prior coverage language clarified around lipid screening frequency and annual testing for certain long-term drug therapies.

    2025-01-01coverage_frequency_change

    Changed lipid panel screening frequency wording and explicitly allowed annual lipid screening for individuals with increased dyslipidemia risk (added obesity/metabolic syndrome and other risk factors); Lp(a) measurement expanded from risk-based to once-per-lifetime for adults (age ≥18).

    2025-11-15clarification

    Clarified Lp(a) screening wording to state measurement is once per lifetime and should occur after the individual is 18 years of age.

    2026-09-15frequency_updateLatest

    Revised routine lipid screening interval from every 4 years to every 5 years (CC1.a.i) and reaffirmed Lp(a) as once-per-lifetime after age 18; moved and reclassified subcriteria to reflect annual testing for elevated-risk conditions.